Overview

VELCADE as Maintenance Treatment in Patients With Multiple Myeloma Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT)

Status:
Unknown status

Trial end date:
2010-10-01

Target enrollment:

Participant gender:

Summary

Protocol DSMM VIII is a multi-center, open-label study evaluating the safety and tolerability, as well as the efficacy, of maintenance treatment with VELCADE (bortezomib) in patients with multiple myeloma with detectable disease activity following tandem high-dose chemotherapy and autologous SCT. The time from SCT to the initiation of VELCADE treatment will be 3 to 6 months.

Phase:

Phase 2

Details

Lead Sponsor:

University of Wuerzburg

Treatments:

Bortezomib